Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Pemvidutide · MD-1373, SP-1373

Peptide · developed by Altimmune

Phase 3 Most advanced trial
ALT Developer
1 Registered trials

What is Pemvidutide?

Pemvidutide is a drug studied in metabolic dysfunction-associated steatohepatitis (MASH), a liver disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MD-1373, SP-1373
Drug type
Peptide
Therapy area
Gastroenterology, Metabolic
Developer
Altimmune, Inc. (ALT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
A35F525WBG

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07795164 Phase 3 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Recruiting ALT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

More from Altimmune

AdCOVID Phase 1 FP-02.2 Vaccine Phase 1 HepTcell Phase 2 NasoShield Phase 1 NasoVAX Phase 2

Follow ALT, the company behind Pemvidutide

See ALT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ALT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.